News

SISCAPA and Biognosys Announce Strategic Collaboration to Deliver End-to-End High-Sensitivity Targeted Protein Quantification Solutions

WASHINGTON, D.C. and ZUERICH, Switzerland – May 19, 2025 – (GlobeNewswire) – SISCAPA Assay Technologies, a global leader in high-sensitivity protein quantitation, and Biognosys, a pioneer in next-generation proteomics, today announced an exclusive strategic collaboration to offer biopharma customers a streamlined end-to-end solution for high-sensitivity protein analysis—from early protein biomarker and drug target discovery, all...

read more

Molecular Partners Reports Financial Results and Highlights from Q1 2025

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 15, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR – Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced...

read more

The University of Gothenburg relies on technology from Biognosys

According to a press release, the Schlieren-based biotech company Biognosys has fully equipped the first laboratory in Europe with its P2 plasma enrichment system. The system has been installed at the Proteomics Core Facility at the University of Gothenburg. This is an important step in making Biognosys' P2 technology more...

read more

CUTISS completes patient recruitment in Phase 2 pediatric burns trial

CUTISS has completed patient recruitment in its Phase 2 clinical trial evaluating the safety and efficacy of denovoSkin™ in children with severe burns. This randomized, controlled trial compares denovoSkin™ to the current standard of care, autografting, using an intra-patient control design. It is one of three Phase 2 trials designed to...

read more